Cite
Estradiol and Spironolactone Plasma Pharmacokinetics Among Brazilian Transgender Women Using HIV Pre-Exposure Prophylaxis: Analysis of Potential Interactions.
MLA
Cattani, Vitória Berg, et al. “Estradiol and Spironolactone Plasma Pharmacokinetics Among Brazilian Transgender Women Using HIV Pre-Exposure Prophylaxis: Analysis of Potential Interactions.” Clinical Pharmacokinetics, vol. 62, no. 7, July 2023, pp. 1031–41. EBSCOhost, https://doi.org/10.1007/s40262-023-01248-0.
APA
Cattani, V. B., Jalil, E. M., Eksterman, L., Torres, T., Wagner Cardoso, S., Castro, C. R. V., Monteiro, L., Wilson, E., Bushman, L., Anderson, P., Veloso, V. G., Grinsztejn, B., Estrela, R., the PrEParadas study team, Hoagland, B., Moura, I., Waite, D. M. M., Vieira, D., Granjeiro, J. R., & Freitas, J. (2023). Estradiol and Spironolactone Plasma Pharmacokinetics Among Brazilian Transgender Women Using HIV Pre-Exposure Prophylaxis: Analysis of Potential Interactions. Clinical Pharmacokinetics, 62(7), 1031–1041. https://doi.org/10.1007/s40262-023-01248-0
Chicago
Cattani, Vitória Berg, Emilia Moreira Jalil, Leonardo Eksterman, Thiago Torres, Sandra Wagner Cardoso, Cristiane R. V. Castro, Laylla Monteiro, et al. 2023. “Estradiol and Spironolactone Plasma Pharmacokinetics Among Brazilian Transgender Women Using HIV Pre-Exposure Prophylaxis: Analysis of Potential Interactions.” Clinical Pharmacokinetics 62 (7): 1031–41. doi:10.1007/s40262-023-01248-0.